Kyverna Therapeutics, Inc.
10-K
March 26, 2026
Key Highlights
- Lead therapy KYV-101 targets autoimmune diseases with potential for a one-time c...
- Preparing for final-stage trial in Stiff Person Syndrome with FDA approval targe...
- Strong cash position of $350 million provides operational runway through 2028.
Read Analysis
🤖 AI Generated